Research programme: bacterial translocase inhibitors - Sankyo/Sequella

Drug Profile

Research programme: bacterial translocase inhibitors - Sankyo/Sequella

Alternative Names: SQ641; SQ922

Latest Information Update: 18 Feb 2011

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Sequella
  • Class Aminoglycosides; Nucleosides
  • Mechanism of Action Phospho-N-acetylmuramoyl pentapeptide transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Crohn's disease; Mycobacterial infections

Most Recent Events

  • 18 Feb 2011 Preclinical trials in Crohn's disease in USA (unspecified route)
  • 13 Oct 2009 Sequella receives SBIR grant from the National Institutes of Health for the development of SQ 641 in Mycobacterial infections
  • 15 Sep 2009 Antimicrobial data from an in vitro study in Mycobacterial infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top